EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

NCT05261139 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: nirmatrelvir
DRUG: ritonavir

Sponsor

Pfizer